AR015446A1 - ANTIGONISTS OF VITRONECTINE RECEPTORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION, ITS USE FOR THE PREPARATION OF A MEDICINE AND INTERMEDIATE COMPOUNDS - Google Patents
ANTIGONISTS OF VITRONECTINE RECEPTORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION, ITS USE FOR THE PREPARATION OF A MEDICINE AND INTERMEDIATE COMPOUNDSInfo
- Publication number
- AR015446A1 AR015446A1 ARP980104604A ARP980104604A AR015446A1 AR 015446 A1 AR015446 A1 AR 015446A1 AR P980104604 A ARP980104604 A AR P980104604A AR P980104604 A ARP980104604 A AR P980104604A AR 015446 A1 AR015446 A1 AR 015446A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- alkyl
- pharmaceutical composition
- composition containing
- vitronectine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Antagonistas de receptores de vitronectina de formula (I) que son utiles en el tratamiento de osteoporosis, en la cual: A es CH2 u O; R1 es H, halo oalquilo C1-6; R2 es H, alquilo C1-6 o CH2NRR; X es O o CH2; Y es seleccionado del grupo de formulas (II); G es NR, S u O; R es H, alquilo C1-6,O-alquilo C1-6, S-alquilo C1-6, NRR o halo; cada R es independientemente H o alquilo C1-6; y S es 0, 1 o 2; o una sal farmacéuticamente aceptable de losmismos, composicion farmacéutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de un medicamento y compuestos intermediarios.Vitronectin receptor antagonists of formula (I) that are useful in the treatment of osteoporosis, in which: A is CH2 or O; R1 is H, halo or C1-6 alkyl; R2 is H, C1-6 alkyl or CH2NRR; X is O or CH2; And it is selected from the group of formulas (II); G is NR, S or O; R is H, C1-6 alkyl, O-C1-6 alkyl, S-C1-6 alkyl, NRR or halo; each R is independently H or C1-6 alkyl; and S is 0, 1 or 2; or a pharmaceutically acceptable salt thereof, pharmaceutical composition containing them, process for its preparation, its use for the preparation of a medicament and intermediates.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5934297P | 1997-09-19 | 1997-09-19 | |
US6343897P | 1997-10-29 | 1997-10-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR015446A1 true AR015446A1 (en) | 2001-05-02 |
Family
ID=26738652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980104604A AR015446A1 (en) | 1997-09-19 | 1998-09-16 | ANTIGONISTS OF VITRONECTINE RECEPTORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION, ITS USE FOR THE PREPARATION OF A MEDICINE AND INTERMEDIATE COMPOUNDS |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1025090A4 (en) |
JP (1) | JP2001517658A (en) |
KR (1) | KR20010024141A (en) |
CN (1) | CN1278250A (en) |
AP (1) | AP2000001766A0 (en) |
AR (1) | AR015446A1 (en) |
AU (1) | AU738433B2 (en) |
BG (1) | BG104314A (en) |
BR (1) | BR9812340A (en) |
CA (1) | CA2303487A1 (en) |
CO (1) | CO5011087A1 (en) |
DZ (1) | DZ2609A1 (en) |
EA (1) | EA200000336A1 (en) |
HU (1) | HUP0003641A3 (en) |
ID (1) | ID24162A (en) |
IL (1) | IL135028A0 (en) |
MA (1) | MA26547A1 (en) |
NO (1) | NO20001407D0 (en) |
NZ (1) | NZ503389A (en) |
OA (1) | OA11341A (en) |
PE (1) | PE122699A1 (en) |
PL (1) | PL339381A1 (en) |
SK (1) | SK4082000A3 (en) |
TR (1) | TR200000721T2 (en) |
TW (1) | TW513303B (en) |
WO (1) | WO1999015508A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4920232A1 (en) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | DIBENZO [A, D] CYCLLOHEPTANE ACETIC ACIDS WITH VITRONECTIN RECEPTOR ANTAGONIST ACTIVITY |
EP1150965A4 (en) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | Benzazepine derivatives as alpha-v integrin receptor antagonists |
DE19936780A1 (en) | 1999-08-09 | 2001-02-15 | Basf Ag | New integrin receptor antagonists |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
FR2806082B1 (en) * | 2000-03-07 | 2002-05-17 | Adir | NOVEL BICYCLIC ANTAGONIST VITRONECTIN RECEPTOR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US6720315B2 (en) | 2000-06-15 | 2004-04-13 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives |
CA2425117A1 (en) * | 2000-10-24 | 2002-05-23 | Merck & Co., Inc. | Dibenzoxazepine alpha v integrin receptor antagonist |
RU2316337C2 (en) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | Combined therapy by using antiangiogenic agents and tnf-alpha |
GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
ES2521679T3 (en) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Specific therapy using integrin ligands for cancer treatment |
EP2101805B1 (en) | 2007-01-18 | 2012-11-07 | Merck Patent GmbH | Integrin ligands for use in treating cancer |
CA2763275A1 (en) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Continuous administration of integrin ligands for treating cancer |
MX2016015467A (en) | 2014-05-30 | 2017-03-23 | Pfizer | Carbonitrile derivatives as selective androgen receptor modulators. |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH450398A (en) * | 1964-02-18 | 1968-01-31 | Hoffmann La Roche | Process for the preparation of dibenzocycloheptatriene compounds |
US3335148A (en) * | 1966-02-17 | 1967-08-08 | Lilly Co Eli | 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof |
US5698551A (en) * | 1995-04-07 | 1997-12-16 | Novo Nordisk A/S | Heterocyclic compounds |
EP0910563B1 (en) * | 1995-06-29 | 2003-05-02 | Smithkline Beecham Corporation | Integrin receptor antagonists |
US5659033A (en) * | 1995-09-13 | 1997-08-19 | Neurogen Corporation | N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands |
EP0946180A4 (en) * | 1996-10-07 | 2003-07-23 | Smithkline Beecham Corp | Method for stimulating bone formation |
CO4920232A1 (en) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | DIBENZO [A, D] CYCLLOHEPTANE ACETIC ACIDS WITH VITRONECTIN RECEPTOR ANTAGONIST ACTIVITY |
-
1998
- 1998-09-16 AR ARP980104604A patent/AR015446A1/en not_active Application Discontinuation
- 1998-09-16 PE PE1998000881A patent/PE122699A1/en not_active Application Discontinuation
- 1998-09-16 DZ DZ980219A patent/DZ2609A1/en active
- 1998-09-18 JP JP2000512816A patent/JP2001517658A/en not_active Withdrawn
- 1998-09-18 AP APAP/P/2000/001766A patent/AP2000001766A0/en unknown
- 1998-09-18 WO PCT/US1998/019466 patent/WO1999015508A1/en not_active Application Discontinuation
- 1998-09-18 PL PL98339381A patent/PL339381A1/en unknown
- 1998-09-18 TR TR2000/00721T patent/TR200000721T2/en unknown
- 1998-09-18 EP EP98947116A patent/EP1025090A4/en not_active Withdrawn
- 1998-09-18 NZ NZ503389A patent/NZ503389A/en not_active IP Right Cessation
- 1998-09-18 BR BR9812340-8A patent/BR9812340A/en not_active Application Discontinuation
- 1998-09-18 SK SK408-2000A patent/SK4082000A3/en unknown
- 1998-09-18 CN CN98810811A patent/CN1278250A/en active Pending
- 1998-09-18 MA MA25266A patent/MA26547A1/en unknown
- 1998-09-18 CO CO98053986A patent/CO5011087A1/en unknown
- 1998-09-18 ID IDW20000468A patent/ID24162A/en unknown
- 1998-09-18 EA EA200000336A patent/EA200000336A1/en unknown
- 1998-09-18 KR KR1020007002901A patent/KR20010024141A/en not_active Application Discontinuation
- 1998-09-18 AU AU93972/98A patent/AU738433B2/en not_active Ceased
- 1998-09-18 IL IL13502898A patent/IL135028A0/en unknown
- 1998-09-18 HU HU0003641A patent/HUP0003641A3/en unknown
- 1998-09-18 CA CA002303487A patent/CA2303487A1/en not_active Abandoned
- 1998-09-23 TW TW087115535A patent/TW513303B/en not_active IP Right Cessation
-
2000
- 2000-03-16 OA OA1200000079A patent/OA11341A/en unknown
- 2000-03-17 NO NO20001407A patent/NO20001407D0/en not_active Application Discontinuation
- 2000-04-07 BG BG104314A patent/BG104314A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU738433B2 (en) | 2001-09-20 |
CN1278250A (en) | 2000-12-27 |
WO1999015508A1 (en) | 1999-04-01 |
HUP0003641A2 (en) | 2001-03-28 |
MA26547A1 (en) | 2004-12-20 |
TR200000721T2 (en) | 2000-11-21 |
NZ503389A (en) | 2002-03-28 |
JP2001517658A (en) | 2001-10-09 |
IL135028A0 (en) | 2001-05-20 |
CA2303487A1 (en) | 1999-04-01 |
BR9812340A (en) | 2001-12-18 |
PE122699A1 (en) | 2000-02-12 |
EA200000336A1 (en) | 2000-10-30 |
PL339381A1 (en) | 2000-12-18 |
OA11341A (en) | 2003-12-10 |
AU9397298A (en) | 1999-04-12 |
NO20001407L (en) | 2000-03-17 |
TW513303B (en) | 2002-12-11 |
BG104314A (en) | 2001-01-31 |
HUP0003641A3 (en) | 2002-10-28 |
NO20001407D0 (en) | 2000-03-17 |
ID24162A (en) | 2000-07-13 |
CO5011087A1 (en) | 2001-02-28 |
KR20010024141A (en) | 2001-03-26 |
EP1025090A1 (en) | 2000-08-09 |
SK4082000A3 (en) | 2000-09-12 |
AP2000001766A0 (en) | 1998-09-18 |
EP1025090A4 (en) | 2000-11-08 |
DZ2609A1 (en) | 2003-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR015446A1 (en) | ANTIGONISTS OF VITRONECTINE RECEPTORS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION, ITS USE FOR THE PREPARATION OF A MEDICINE AND INTERMEDIATE COMPOUNDS | |
ES2149767T3 (en) | NEW MEDICAL USE FOR TACHYQUIN ANTAGONISTS. | |
PA8431301A1 (en) | METALOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES AND USEFUL METHODS AND INTERMEDIATES FOR THEIR PREPARATION | |
AR003453A1 (en) | PLATELET AGGREGATE INHIBITORS, THEIR USE IN THE MANUFACTURE OF MEDICINES, THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THE PROCEDURE FOR THE PREPARATION OF SUCH INHIBITORS | |
MXPA05011710A (en) | Fused pyrimidine derivatives with crf activity. | |
UY25804A1 (en) | 4-AROILPIPERIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF CCR-3 RECEPTORS | |
ES2158778B1 (en) | PAROXETINE SALT COMPOUNDS, THEIR PREPARATION AND USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
UY27336A1 (en) | 4-PIPERACINYLINDOL DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY | |
AR003944A1 (en) | QUINAZOLINE DERIVATIVES, HYDROCHLORIDE SALT, PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USE | |
AR009052A1 (en) | THENOPYRIMIDINES, A PROCEDURE FOR THEIR PREPARATION, USE OF THE SAME TO PREPARE A MEDICINAL PRODUCT, PHARMACEUTICAL PREPARATIONS THAT CONSTITUTE THEM AND A PROCEDURE TO OBTAIN THESE PHARMACEUTICAL PREPARATIONS | |
ES2160648T3 (en) | DERIVATIVES OF PIRIDINE. | |
AR024060A1 (en) | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | |
EA200600811A1 (en) | NEW TETRAHYDROSPIRO {PIPERIDIN-2,7'-PYRROLO [3,2-b] PYRIDINE} DERIVATIVES AND NEW INDOLA DERIVATIVES, APPLICATION FOR THE TREATMENT OF DISORDERS RELATED TO 5-HT-RECEPTOR | |
NO20025641D0 (en) | Substituted 1-aminoalkyl lactams and their use as muscarinic receptor antagonists | |
NO20025640D0 (en) | Substituted 1-aminoalkyl lactams and their use as muscarinic receptor antagonists | |
YU53100A (en) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists | |
DE69018678D1 (en) | Tricyclic lactam derivatives and pharmaceutical compositions containing them. | |
RU99127433A (en) | ERGOLINE DERIVATIVES AND THEIR APPLICATION AS ANTAGONISTS OF SOMATOSTATIN RECEPTORS | |
EA200500882A1 (en) | N-ARILSULFONIL-3-AMINOALKOXIINDOLES | |
MXPA04005076A (en) | 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists. | |
BR0214649A (en) | Aminotetraline derivatives as muscarinic receptor antagonists | |
AR035006A1 (en) | DERIVATIVE OF NAFTIRIDIN-DIBENZO [A, D] CICLOHEPTENO-10-ACETICO, PHARMACEUTICAL COMPOSITION, AND THE USE OF THAT DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
AR005102A1 (en) | COMPOUNDS DERIVED FROM OCTAHIDRO-PIRROLO [1,2-A] -PYRAZINE 2,7-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS AND USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
MXPA04006113A (en) | Triazolo-quinolin derivatives useful as adenosine receptor ligands. | |
PT84934A (en) | NOVEL DERIVATIVES OF SYNERGISTINES PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |